C-Ray Therapeutics
↗Chengdu, China
C-Ray Therapeutics is an innovative biopharmaceutical company established in 2021 and headquartered in Chengdu Medical City, China. The company is dedicated to the development, manufacturing, clinical application, and commercialization of radiopharmaceuticals, primarily targeting major diseases such as oncology. C-Ray operates as both a pharmaceutical developer and a comprehensive CRDMO (Contract Research, Development, and Manufacturing Organization) service provider for radiopharmaceuticals, supporting partners throughout the entire drug development and manufacturing lifecycle.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Founded:2021
Ownership:private
Status:operating
FUNDING
Stage:Series A+
Total Raised:$100M+
Investors:Shenzhen Capital Group Co., Ltd. (SCGC) - Manufacturing Transformation and Upgrading New Materials Fund, TaiLong Capital, GL Ventures, 3SBio, Guanghua Wutong, HBM Partners (Hillhouse Capital Management), 6 Dimensions Capital (incubator)
PIPELINE
Stage:Preclinical|Phase 1|Phase 2|Phase 3|Commercial
Lead Drug Stage:Multiple programs in development, including support for partner Biokin's [177Lu]-BL-ARC001 (NMPA-approved IND)
Modalities:Radiopharmaceuticals, Radionuclide Drug Conjugates (RDC), Alpha-emitters, Beta-emitters (Lutetium-177), Diagnostic radiopharmaceuticals, Therapeutic radiopharmaceuticals, Small molecule radiolabeled drugs, Peptide conjugate radionuclides
Trial Phases:Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Biokin Pharmaceutical - RDC drug development (CRDMO partner for [177Lu]-BL-ARC001), Mednovo - Phase III clinical trial support for Lutetium [177Lu] Oxodotreotide Injection, 3SBio - Strategic investor exploring collaboration on radioactive drug R&D, Multiple academic and clinical partners for IIT trials
COMPETITION
Position:Emerging|Niche Player
Competitors:Novartis (radioligand therapy leader, market cap $207.65B), Bayer, Lantheus Medical Imaging, Eli Lilly (acquired Point Biopharma for $1.4B), Bristol Myers Squibb (invested $4.1B in RayzeBio), Atonco Pharma (France), GlyTherix (Australia), Ablaze Pharmaceuticals (China) +3 more
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of C-Ray Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with C-Ray Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.